NCT00657657View on ClinicalTrials.gov

Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B

A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.

Trial Locations (1)

10330

GSK Investigational Site, Bangkok

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00657657 - Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine | Biotech Hunter | Biotech Hunter